PURPOSE: A high-speed mechanical clot macerator was tested in vitro, and the distributions and sizes of residual particles produced by this device were determined. MATERIALS AND METHODS: Human thrombi aged for 4 days and 10 days were macerated using a recirculation-type Amplatz thrombectomy device with an 8-F, high-speed screw propeller. The device was activated for 15, 30, and 60 seconds. Two different methods of particle measurement were used to determine overall particle distribution and to determine the size and number of large particles. RESULTS: The recirculation device liquefied 99.2% of 4-day-old and 98.8% of 10-day-old thrombi, producing particles ranging in size from 13 to 1,000 microns; all particles were smaller than 1,000 microns. Particle size and distribution results were identical for the 30-second and 60-second activation times. CONCLUSION: The recirculation-type thrombectomy device appears to perform well as a method of macerating human thrombi. Clinical trials need to be conducted to test the device further and to determine if it can be used safely on venous as well as arterial occlusions.
PURPOSE: A high-speed mechanical clot macerator was tested in vitro, and the distributions and sizes of residual particles produced by this device were determined. MATERIALS AND METHODS:Humanthrombi aged for 4 days and 10 days were macerated using a recirculation-type Amplatz thrombectomy device with an 8-F, high-speed screw propeller. The device was activated for 15, 30, and 60 seconds. Two different methods of particle measurement were used to determine overall particle distribution and to determine the size and number of large particles. RESULTS: The recirculation device liquefied 99.2% of 4-day-old and 98.8% of 10-day-old thrombi, producing particles ranging in size from 13 to 1,000 microns; all particles were smaller than 1,000 microns. Particle size and distribution results were identical for the 30-second and 60-second activation times. CONCLUSION: The recirculation-type thrombectomy device appears to perform well as a method of macerating humanthrombi. Clinical trials need to be conducted to test the device further and to determine if it can be used safely on venous as well as arterial occlusions.
Authors: Xi Zhang; Gabe E Owens; Charles A Cain; Hitinder S Gurm; Jonathan Macoskey; Zhen Xu Journal: Ultrasound Med Biol Date: 2016-05-07 Impact factor: 2.998
Authors: Aiwei Shi; Jonathan Lundt; Zilin Deng; Jonathan Macoskey; Hitinder Gurm; Gabe Owens; Xi Zhang; Timothy L Hall; Zhen Xu Journal: Ultrasound Med Biol Date: 2018-09-30 Impact factor: 2.998
Authors: Viktor Bollen; Samuel A Hendley; Jonathan D Paul; Adam D Maxwell; Kevin J Haworth; Christy K Holland; Kenneth B Bader Journal: Ultrasound Med Biol Date: 2019-11-27 Impact factor: 2.998
Authors: Xi Zhang; Lifang Jin; Eli Vlaisavljevich; Gabe E Owens; Hitinder S Gurm; Charles A Cain; Zhen Xu Journal: IEEE Trans Ultrason Ferroelectr Freq Control Date: 2015-12 Impact factor: 2.725